False Claims Act: US Justice Department Gives Pharma Early Christmas Present
Executive Summary
Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.
You may also be interested in...
Pharma Could Face Fewer False Claims Act Suits If Supreme Court Concurs With Government
High court is to determine whether the government can dismiss an FCA complaint after initially declining to take it on. In recent years, the government has dismissed numerous qui tam suits against pharma companies in which it did not intervene.
Rx Drug Promotion: Potential Enforcement Worries
Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.
Will US Government Pursue Fewer False Claims Act Cases In 2019?
Fallout from Supreme Court's Escobar decision and Department of Justice memos could impact types of healthcare fraud complaints in which the government intervenes.